Zacks Research Issues Negative Forecast for IRWD Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Stock analysts at Zacks Research lowered their Q2 2025 earnings per share estimates for Ironwood Pharmaceuticals in a research note issued to investors on Wednesday, May 28th. Zacks Research analyst R. Department now expects that the biotechnology company will post earnings per share of ($0.04) for the quarter, down from their previous forecast of $0.03. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals' FY2025 earnings at $0.07 EPS, Q2 2026 earnings at $0.06 EPS and FY2027 earnings at ($0.01) EPS.

A number of other brokerages have also weighed in on IRWD. Citizens Jmp lowered shares of Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Monday, April 14th. Jefferies Financial Group reiterated a "hold" rating and issued a $0.70 target price (down previously from $8.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Wells Fargo & Company reiterated an "equal weight" rating and issued a $1.00 target price (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Wall Street Zen raised Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, Leerink Partners reduced their price objective on Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating on the stock in a research note on Monday, April 14th. Seven investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $4.78.

Ironwood Pharmaceuticals Stock Down 5.2%

Shares of IRWD traded down $0.03 during mid-day trading on Monday, hitting $0.57. The company had a trading volume of 2,959,362 shares, compared to its average volume of 2,576,749. The business's 50-day simple moving average is $0.84 and its 200-day simple moving average is $2.21. Ironwood Pharmaceuticals has a 1-year low of $0.53 and a 1-year high of $7.11. The stock has a market cap of $92.40 million, a PE ratio of -19.03 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.09). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business had revenue of $41.14 million during the quarter, compared to analyst estimates of $67.02 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Armistice Capital LLC lifted its position in Ironwood Pharmaceuticals by 44.7% during the 1st quarter. Armistice Capital LLC now owns 13,700,000 shares of the biotechnology company's stock worth $20,139,000 after acquiring an additional 4,232,000 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Ironwood Pharmaceuticals by 5.5% during the fourth quarter. Renaissance Technologies LLC now owns 9,066,241 shares of the biotechnology company's stock worth $40,163,000 after purchasing an additional 469,043 shares in the last quarter. Millennium Management LLC lifted its position in shares of Ironwood Pharmaceuticals by 186.6% during the first quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company's stock worth $9,349,000 after purchasing an additional 4,140,439 shares in the last quarter. Jane Street Group LLC lifted its position in shares of Ironwood Pharmaceuticals by 740.5% during the first quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company's stock worth $5,160,000 after purchasing an additional 3,092,475 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Ironwood Pharmaceuticals by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 3,306,570 shares of the biotechnology company's stock worth $14,652,000 after buying an additional 13,028 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.